Life Biosciences is a technology company.
Life Biosciences has raised $82.0M across 1 funding round.
Life Biosciences has raised $82.0M in total across 1 funding round.
Life Biosciences has raised $82.0M in total across 1 funding round.
Life Biosciences's investors include Blockchain.com Ventures, Faction VC, Galaxy Interactive, NGC Ventures, Oyster Ventures, Pillar VC, Sunset Ventures, Julian Shapiro, Sahin Boydas.
Life Biosciences is a private biopharmaceutical company founded in 2016 and headquartered in Boston, Massachusetts, that develops cellular rejuvenation therapies to reverse and prevent age-related diseases.[1][2][3][4] It operates as a biotech platform identifying, incubating, and commercializing breakthrough treatments targeting the biology of aging, including a novel partial epigenetic reprogramming platform, while serving the healthcare and biotechnology sectors through research and therapeutics that extend healthy lifespan.[1][2][3][4] The company has raised $130.6M in funding and acts as the parent to daughter companies, each advancing specific aging-focused technologies toward market.[1][2]
This addresses a massive market need: 80% of people over 60 have at least one chronic illness, 50% have two or more, and 30% of those 65+ in OECD countries require assistance with daily activities, with the global population over 60 projected to nearly double from 12% in 2015 to 22% by 2050.[3]
Life Biosciences was founded in 2016 in Boston as a platform to tackle aging through targeted therapeutics, challenging the notion that aging results from random wear and tear by focusing on discrete biological mechanisms.[2][3] Key details on specific founders are not detailed in available sources, but the company emerged from groundbreaking research licensed exclusively from leading academic institutions, supported by strong composition-of-matter and method-of-use patents.[3] Early momentum built through its model of incubating daughter companies with promising technologies, raising $130.6M across funding stages while advancing platforms like partial epigenetic reprogramming to address aging's root causes.[1][2][4]
Life Biosciences rides the surging cellular rejuvenation trend in biotech, where aging is treated as a treatable disease driven by targetable mechanisms rather than inevitable decline, aligning with competitors like Altos Labs and Turn Biotechnologies.[2][4] Timing is ideal amid a demographic shift—the world's over-60 population doubling by 2050—and rising demand for solutions to chronic illnesses burdening healthcare systems.[3] Favorable market forces include advances in epigenetic reprogramming and mRNA technologies, plus investor interest evidenced by $130.6M raised, positioning Life to influence the ecosystem by incubating spinouts and validating aging as a multi-billion-dollar therapeutic frontier.[1][2][3]
Life Biosciences is poised to advance its epigenetic reprogramming platform into clinical stages, potentially yielding first-in-class therapies for high-unmet-need age-related diseases like neurodegeneration and frailty.[4] Trends like AI-driven drug discovery, expanded longevity funding, and global aging will propel growth, with daughter company spinouts amplifying impact. Its influence may evolve from incubator to category leader, redefining aging biotech and extending healthy lifespans amid a doubling elderly population—turning a demographic crisis into a therapeutic opportunity.[3]
Life Biosciences has raised $82.0M across 1 funding round. Most recently, it raised $82.0M Series C in January 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2022 | $82.0M Series C | Blockchain.com Ventures, Faction VC, Galaxy Interactive, NGC Ventures, Oyster Ventures, Pillar VC, Sunset Ventures, Julian Shapiro, Sahin Boydas |